sapanisertib   Click here for help

GtoPdb Ligand ID: 7933

Synonyms: INK 128 | INK-128 | INK128 | MLN0128 | TAK-228
PDB Ligand Antimalarial Ligand
Compound class: Synthetic organic
Comment: Sapanisertib (INK128) is an ATP-competitive inhibitor of mTOR in mTORC1 and mTORC2 complexes, that exhibits potent anti-tumour activity [2-4].

The compound also has antimalarial activity. The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 121.67
Molecular weight 309.13
XLogP 1.9
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
Isomeric SMILES Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
InChI InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
InChI Key GYLDXIAOMVERTK-UHFFFAOYSA-N
References
1. Arendse LB, Murithi JM, Qahash T, Pasaje CFA, Godoy LC, Dey S, Gibhard L, Ghidelli-Disse S, Drewes G, Bantscheff M et al.. (2022)
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages.
Sci Transl Med, 14 (667): eabo7219. [PMID:36260689]
2. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ et al.. (2012)
The translational landscape of mTOR signalling steers cancer initiation and metastasis.
Nature, 485 (7396): 55-61. [PMID:22367541]
3. Jessen K, Wang S, Kessler, L, Guo X, Kucharski J, Staunton J, Lan L, Elia M, Stewart J, Brown J et al.. (2009)
INK128 is a potent and selective TORC1/2 inhibitor with broad oral anti-tumor activity.[Abstract].
Mol Cancer Ther, 8 (12 (Supplement)): B148.
4. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. (2009)
mTOR Mediated Anti-Cancer Drug Discovery.
Drug Discov Today Ther Strateg, 6 (2): 47-55. [PMID:20622997]
5. Schenone S, Brullo C, Musumeci F, Radi M, Botta M. (2011)
ATP-competitive inhibitors of mTOR: an update.
Curr Med Chem, 18 (20): 2995-3014. [PMID:21651476]